Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease
largely of complement dysregulation. This advance facilitated the development of novel …

Background Atypical hemolytic uremic syndrome (aHUS) is a rare, complement-mediated
disease associated with poor outcomes if untreated. Ravulizumab, a long-acting C5 inhibitor …

Atypical hemolytic uremic syndrome (aHUS) in childhood is a rare disease associated with
high morbidity and mortality. Most cases progress to end-stage renal failure. In …

Atypical hemolytic uremic syndrome (aHUS) is a rare, chronic, life-threatening disease due
to complement dysregulation. The use of early-onset plasma therapy is recommended, but …

With the introduction of the complement C5-inhibitor eculizumab, a new era was entered for
patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very …

The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic
syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter …

Background There are limited long-term outcome data in eculizumab-treated patients with
atypical hemolytic uremic syndrome (aHUS). We report final results from the largest …

Atypical hemolytic uremic syndrome (aHUS) is a heterogeneous disease that is caused by
defective complement regulation in over 50% of cases. Mutations have been identified in …

Background Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening
disease of chronic uncontrolled complement activation leading to thrombotic …

The haemolytic uraemic syndrome (HUS) includes the triad of haemolytic anaemia,
thrombocytopenia, and acute renal failure. The classical form [D (+) HUS] is caused by …